José Baselga, a 59-year-old Spanish doctor born in Barcelona, has been signed by British pharmaceutical company AstraZeneca to become his director of research and development of products against cancer.
The Spanish oncologist signs for the fifth largest company in the world just four months after his controversy resignation as medical director of the Memorial Sloan Kettering Cancer Center, after the New York Times revealed that disclosed millions of dollars in payments to various pharmaceutical companies. Baselga is considered one of the best worldwide specialists in the fight against cancer.
Pascual Soriot, CEO of AstraZeneca, said that the Spanish experience means more scientific excellence for his team: «José is an outstanding leading scientist in oncology, and its research and clinical achievements have led to the development of several innovative medicines. He is a leader in international thinking about cancer care and clinical research. "
Baselga worked at Memorial Sloan Kettering from 2012 until his resignation in September of last year, as well as serving as Professor at Weill Cornell Medical College. It was also Professor at the prestigious Harvard University and went director of oncology at Massachusetts General Hospital Cancer and the oncology institute at Vall d'Hebron Hospital, in Barcelona. "After more than thirty years helping to develop medicines in this area, it is a real privilege to work together with AstraZeneca's great oncology experience. Integrating in a unit from the discovery to the final development will make the process more agile and accelerate the work of taking transformative medicines for patients. ANDIt's really a dream job », Baselga affirmed after knowing his signing.